131852-53-4

Usage

Uses

Used in Pharmaceutical Manufacturing:
(S)-(-)-1-Benzyl-3-(BOC-amino)pyrrolidine is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique molecular structure and stereo-specificity make it a valuable component in the development of chiral molecules, which are crucial for the effectiveness and safety of many drugs.
Used in Advanced Organic Synthesis:
In the field of organic chemistry, (S)-(-)-1-Benzyl-3-(BOC-amino)pyrrolidine serves as a key building block in the synthesis of complex organic molecules. Its presence in the molecular structure can influence the reactivity and properties of the final product, making it an essential component in the creation of novel compounds with potential applications in various industries.
Used in Research and Development:
(S)-(-)-1-Benzyl-3-(BOC-amino)pyrrolidine is also utilized in research settings to study the properties and reactivity of complex organic molecules. Its unique structure and the presence of the BOC-protected amine provide opportunities for investigating new reaction pathways and understanding the fundamental principles of organic chemistry. This knowledge can then be applied to the development of new synthetic methods and the creation of innovative compounds with potential applications in various fields.

InChI:InChI=1/C16H24N2O2/c1-16(2,3)20-15(19)17-14-9-10-18(12-14)11-13-7-5-4-6-8-13/h4-8,14H,9-12H2,1-3H3,(H,17,19)/t14-/m0/s1

Upstream product

• 100-46-9 benzylamine 
• 176970-13-1 [(S)-2-(tert-butoxycarbonyamino)butane-1 ,4-diyl dimethanesulfonate] 
• 24424-99-5 di-tert-butyl dicarbonate 
• 114715-38-7 (3S)-1-benzyl-3-pyrrolidinamine 
• 101385-90-4 (R)-N-benzyl-3-hydroxypyrrolidine 
• 114636-29-2 (3S)-3-azido-1-(phenylmethyl)pyrrolidine 
• 130622-08-1 dimethyl N-tert-butoxycarbonyl-L-aspartate 
• 100-52-7 benzaldehyde 
• 122536-76-9 3(S)-(tert-butoxycarbonylamino)pyrrolidine 
• 128427-10-1 (S)-2-(tert-butoxycarbonylamino)-1,4-butanediol 
• 114715-35-4 (R)-3-methanesulfonyloxy-1-(phenylmethyl)-pyrrolidine 

Downstream Products

• 169749-99-9 (3S)-(-)-1-benzyl-3-(methylamino)pyrrolidine 
• 122536-76-9 3(S)-(tert-butoxycarbonylamino)pyrrolidine 
• 114636-30-5 (S)-(-)-1-benzyl-3-acetylaminopyrrolidine 
• 178688-10-3 ((S)-1-Cyclohexyl-pyrrolidin-3-yl)-carbamic acid tert-butyl ester 
• 114715-38-7 (3S)-1-benzyl-3-pyrrolidinamine 

Relevant academic research and scientific papers

BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS

This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

PROCESS FOR PRODUCING NITROGENOUS HETEROCYCLIC COMPOUND

A nitrogenous heterocyclic compound such as 3-aminopyrrolidine derivative is produced by hydrogenolysis of an N-substituted nitrogenous heterocyclic compound with normal pressure hydrogen in a water-based solvent in presence of a catalyst. In the case an optically active 1-substituted-3-aminopyrrrolidine derivative is used as a raw material, an optically active 3-aminopyrrolidine derivative can be obtained as a product practically without racemination.

Synthesis and structure-activity relationships of naphthamides as dopamine D3 receptor ligands

A series of naphthamides were synthesized, and the affinities of these compounds were determined for dopamine D2 and D3 receptors using radioligand binding techniques. The naphthamide compounds that were prepared include N-(1- alkylp

An efficient conversion of chiral α-amino acids to enantiomerically pure 3-amino cyclic amines

Enantiomerically pure 3-amino cyclic amines such as 3-amino pyrrolidine, 3-amino piperidine, and 2,3,4,5,6,7-hexahydro-1H-azepine have been synthesized in high yields from the optically active natural α-amino acids such as L-aspartic acid, L-glutamic acid, L-2-aminoadipic acid, and their enantiomers.

Quinolizinone type compounds

Antibacterial compounds having the formula STR1 and the pharmaceutically acceptable salts, esters and amides thereof, preferred examples of which include those compounds wherein A is =CR6 --; R1 is cycloalkyl of from three to eight carbon atoms or substituted phenyl; R2 is selected from the group consisting of STR2 R3 is halogen; R4 is hydrogen, loweralkyl, a pharmaceutically acceptable cation, or a prodrug ester group; R5 is hydrogen, loweralkyl, halo(loweralkyl), or --NR13 R14 ; and R6 is halogen, loweralkyl, halo(loweralkyl), hydroxy-substituted loweralkyl, loweralkoxy(loweralkyl), loweralkoxy, or amino(loweralkyl), as well as pharmaceutical compositions containing such compounds and the use of the same in the treatment of bacterial infections.